Unknown

Dataset Information

0

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.


ABSTRACT:

Background

Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies target the membrane distal immunoglobulin V (IgV) domain of the CD33 extracellular domain.

Methods

In this manuscript, we present data on three bispecific antibodies (BsAbs) against the CD33 IgV and membrane proximal immunoglobulin C (IgC) domains. We use in vitro binding and cytotoxicity assays to show the effect of these BsAbs on AML cell lines. We also use immunodeficient mice-bearing leukemias from cell lines and patient-derived xenografts to show the effect of these BsAbs in vivo.

Results

In vitro, the IgV-targeting BsAb had higher binding to AML cell lines using flow cytometry and delivered more potent cytotoxicity in T-cell-dependent cytotoxicity assays; importantly, the IgC domain-targeting outperformed the IgV domain-targeting BsAb in medullary and extramedullary leukemia animal models.

Conclusions

These data support further clinical development of this BsAb for first-in-human phase I clinical trial.

SUBMITTER: Hoseini SS 

PROVIDER: S-EPMC8154967 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5998923 | biostudies-literature
| S-EPMC8722076 | biostudies-literature
| S-EPMC5386336 | biostudies-literature
| S-EPMC6295344 | biostudies-literature
| S-EPMC4492699 | biostudies-literature
| S-EPMC6217777 | biostudies-literature
| S-EPMC7731630 | biostudies-literature
| S-EPMC4498153 | biostudies-literature
| S-EPMC6981622 | biostudies-literature
| S-EPMC7059518 | biostudies-literature